Nanoemulsions: Formulation, characterization, biological fate, and potential role against COVID-19 and other viral outbreaks
Source abstract
Abstract
Viral diseases are emerging as global threats. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that causes coronavirus disease (COVID-19), has severe global impacts. Safety, dosage, and potency of vaccines recently approved for emergency use against SARS-CoV-2 need further evaluation. There is still no effective treatment against COVID-19; therefore, safe, and effective vaccines or therapeutics against SARS-CoV-2 are urgently needed. Oil-in-water nanoemulsions (O/W NEs) are emerging as sophisticated, protective, and therapeutic platforms. Encapsulation capacity, which offers better drug pharmacokinetics, coupled with the tunable surfaces present NEs as promising tools for pharmaceutical applications. The challenges facing drug discovery, and the advancements of NEs in drug delivery demonstrate the potential of NEs against evolving diseases, like COVID-19. Here we summarize current COVID-19 knowledge and discuss the composition, stability, preparation, characterization, and biological fate of O/W NEs. We also provide insights into NE structural-functional properties that may contribute to therapeutic or preventative solutions against COVID-19.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Inhalation and Respiratory Drug Delivery · Advancements in Transdermal Drug Delivery · Vibrio bacteria research studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Nanoemulsions for drug delivery
2. Nanoemulsion of Foeniculum vulgare essential oil: a propitious striver against weeds of Triticum aestivum10.1016/j.indcrop.2021.113601 ↗
3. Natural antimicrobial-loaded nanoemulsions for the control of food spoilage/pathogenic microorganisms10.1016/j.cis.2021.102504 ↗
4. Nanoemulsion-based delivery approaches for nutraceuticals: fabrication, application, characterization, biological fate, potential toxicity and future trends10.1039/D0FO02686G ↗
5. Toward the formulation of bio-cosmetic nanoemulsions: from plant-derived to microbial-derived ingredients
6. Chapter 17 - Nanoemulsion in cosmetic: From laboratory to market
7. Chapter 1 - general aspects of nanoemulsions and their formulation
8. Multiple nanoemulsions10.1038/s41578-019-0161-9 ↗
9. Nanoemulsions in drug delivery: formulation to medical application10.2217/nnm-2018-0088 ↗
10. Nanoemulsion as a feasible and biocompatible carrier for ocular delivery of travoprost: improved pharmacokinetic/pharmacodynamic properties10.1016/j.ijpharm.2020.119402 ↗
11. Development and in vitro characterization of transferrin-decorated nanoemulsion utilizing hydrophobic ion pairing for targeted cellular uptake
12. A Nano-emulsion platform functionalized with a fully human scFv-fc antibody for atheroma targeting: towards a theranostic approach to atherosclerosis10.3390/ijms22105188 ↗
13. Protection of protein drugs by self-emulsified nanoemulsion against proteolysis10.1016/j.xphs.2020.05.005 ↗
14. Comparison of different protein emulsifiers on physicochemical properties of β-carotene-loaded Nanoemulsion: effect on formation, stability, and in vitro digestion10.3390/nano11010167 ↗
15. Brucine PEGylated nanoemulsion: in vitro and in vivo evaluation10.1016/j.colsurfa.2020.125618 ↗
16. Nanomedicine based approaches for combating viral infections10.1016/j.jconrel.2021.08.011 ↗
17. Development of nanoparticle-delivery systems for antiviral agents: a review10.1016/j.jconrel.2021.01.017 ↗
18. Genomic characterization of a novel SARS-CoV-210.1016/j.genrep.2020.100682 ↗
19. A new coronavirus associated with human respiratory disease in China10.1038/s41586-020-2008-3 ↗
20. The architecture of SARS-CoV-2 transcriptome10.1016/j.cell.2020.04.011 ↗
21. The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles10.1128/JVI.01052-08 ↗
22. Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E10.1099/vir.0.80671-0 ↗
23. The crystallography of SARS-CoV2 suggests its deactivation, ran
24. Membrane tension may define the deadliest virus infection10.1016/j.colcom.2020.100338 ↗
25. Coronaviruses: an overview of their replication and pathogenesis10.1007/978-1-4939-2438-7_1 ↗
26. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies10.3390/v12030254 ↗
27. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein10.1016/j.cell.2020.02.058 ↗
28. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2
29. Ikarugamycin: a natural product inhibitor of clathrin-mediated endocytosis10.1111/tra.12425 ↗
30. Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms10.1128/JVI.00998-13 ↗
31. Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol10.15252/embj.2020106057 ↗
32. Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial10.1136/rmdopen-2020-001455 ↗
33. A review on remdesivir: a possible promising agent for the treatment of COVID-1910.2147/DDDT.S261154 ↗
34. A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-210.1016/j.chom.2020.03.002 ↗
35. Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission10.1128/JVI.01394-09 ↗
36. The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement
37. Emerging coronaviruses: genome structure, replication, and pathogenesis10.1002/jmv.25681 ↗
38. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design10.1111/febs.12936 ↗
39. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors10.1126/science.abb3405 ↗
40. Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-210.1002/jmv.25731 ↗
41. SARS-CoV-2 and the human-animal interface: outbreaks on mink farms10.1016/S1473-3099(20)30912-9 ↗
42. Real-time tracking of self-reported symptoms to predict potential COVID-1910.1038/s41591-020-0916-2 ↗
43. Acute respiratory failure in COVID-19: is it “typical” ARDS?10.1186/s13054-020-02911-9 ↗
44. Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England
45. Emergence of a novel SARS-CoV-2 strain in Southern California, USA
46. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa
47. SARS-CoV-2 evolution and vaccines: cause for concern?10.1016/S2213-2600(21)00075-8 ↗
48. Temporal dynamics in viral shedding and transmissibility of COVID-19
49. Development of a novel oil-in-water emulsion and evaluation of its potential adjuvant function in a swine influenza vaccine in mice10.1186/s12917-018-1719-2 ↗
50. O/W Nanoemulsion as an adjuvant for an inactivated H3N2 influenza vaccine: based on particle properties and mode of carrying10.2147/IJN.S232677 ↗
51. A novel combination of intramuscular vaccine adjuvants, nanoemulsion and CpG produces an effective immune response against influenza a virus10.1016/j.vaccine.2020.03.026 ↗
52. Formulation and characterization of nanoemulsion intranasal adjuvants: effects of surfactant composition on mucoadhesion and immunogenicity10.1021/mp4005029 ↗
53. The effects of oil-in-water Nanoemulsion polyethylene glycol surface density on intracellular stability, pharmacokinetics, and biodistribution in tumor bearing mice10.1007/s11095-014-1553-6 ↗
54. Insights into the interfacial structure–function of poly (ethylene glycol)-decorated peptide-stabilised nanoscale emulsions10.1039/C7SM01614J ↗
55. Development of EGFR-targeted Nanoemulsion for imaging and novel platinum therapy of ovarian cancer10.1007/s11095-014-1345-z ↗
56. Chapter 6 - surfactants and nanoscience
57. Formation and stability of nano-emulsions10.1016/j.cis.2003.10.023 ↗
58. Microbial production of surfactants and their commercial potential
59. Biosurfactants: a sustainable replacement for chemical surfactants?10.1007/s10529-012-0956-x ↗
60. Rhamnolipids: diversity of structures, microbial origins and roles10.1007/s00253-010-2498-2 ↗
61. Separation and characterization of Surfactin isoforms produced byBacillus subtilis OKB 10510.1006/jcis.1998.5558 ↗
62. Foaming properties of a peptide designed to form stimuli-responsive interfacial films10.1039/b609960b ↗
63. Peptide surfactants (Pepfactants) for switchable foams and emulsions10.1002/apj.66 ↗
64. A designed biosurfactant protein for switchable foam control10.1002/cphc.201100082 ↗
65. Molecular dynamics simulation of protein biosurfactants10.3390/colloids2030039 ↗
66. Biosurfactants, natural alternatives to synthetic surfactants: physicochemical properties and applications10.1016/j.cis.2019.102061 ↗
67. Hasenhuettl · 2008
68. Microbial biosurfactants: challenges and opportunities for future exploitation10.1016/j.tibtech.2012.07.003 ↗
69. Biosurfactants: potential applications in medicine10.1093/jac/dkl024 ↗
70. Biomedical and therapeutic applications of biosurfactants
71. Potential therapeutic applications of biosurfactants10.1016/j.tips.2013.10.002 ↗
72. Biosurfactants’ potential role in combating COVID-19 and similar future microbial threats10.3390/app11010334 ↗
73. Mechanism of inactivation of enveloped viruses by the biosurfactant Surfactin fromBacillus subtilis10.1006/biol.1997.0099 ↗
74. Synthetic surfactin analogues have improved anti-PEDV properties10.1371/journal.pone.0215227 ↗
75. Biosurfactants: a Covid-19 perspective
76. Self-assembly of designer biosurfactants10.1039/c1sm05197k ↗
77. Impact of site-specific bioconjugation on the interfacial activity of a protein biosurfactant10.1021/acs.langmuir.9b01684 ↗
78. Biosurfactants and surfactants interacting with membranes and proteins: same but different?10.1016/j.bbamem.2016.09.024 ↗
79. Templating core-shell particles using metal ion-chelating biosurfactants
80. Emulsion-templated silica nanocapsules formed using bio-inspired silicification
81. Towards designer nanoemulsions for precision delivery of therapeutics10.1016/j.coche.2013.12.007 ↗
82. Edible Nanoemulsions as carriers of active ingredients: a review10.1146/annurev-food-030216-025908 ↗
83. An overview of micro- and Nanoemulsions as vehicles for essential oils: formulation, preparation and stability10.3390/nano10010135 ↗
84. Some considerations about the hydrophilic–lipophilic balance system10.1016/j.ijpharm.2007.12.034 ↗
85. Nanoemulsions: formation, properties and applications10.1039/C5SM02958A ↗
86. Nanoemulsions: Preparation, structure, functional properties and their antimicrobial effects
87. Design and production of nanoparticles formulated from nano-emulsion templates—a review10.1016/j.jconrel.2008.02.007 ↗
88. Food-grade nanoemulsions: formulation, fabrication, properties, performance, biological fate, and potential toxicity10.1080/10408398.2011.559558 ↗
89. Techniques for formulation of Nanoemulsion drug delivery system: a review10.3746/pnf.2019.24.3.225 ↗
90. Formulation of nanoemulsion: a comparison between phase inversion composition method and high-pressure homogenization method10.3109/10717544.2013.866992 ↗
91. Nano-emulsions: formation by low-energy methods10.1016/j.cocis.2012.07.003 ↗
92. Nanoemulsion: process selection and application in cosmetics--a review10.1111/ics.12260 ↗
93. Nanoemulsion: concepts, development and applications in drug delivery10.1016/j.jconrel.2017.03.008 ↗
94. Oil–water de-emulsification using ultrasonic technology10.1016/j.ultsonch.2014.05.014 ↗
95. Nanoscale nutrient delivery systems for food applications: improving bioactive dispersibility, stability, and bioavailability10.1111/1750-3841.12919 ↗
96. The use of ultrasonics for nanoemulsion preparation10.1016/j.ifset.2007.07.005 ↗
97. Preparation of food flavor Nanoemulsions by high- and low-energy emulsification approaches10.1007/s12393-019-09201-3 ↗
98. Chapter 5 - general principles of Nanoemulsion formation by high-energy mechanical methods
99. Formation of capsaicin loaded nanoemulsions with high pressure homogenization and ultrasonication10.1016/j.lwt.2018.05.043 ↗
100. Effect of emulsifier type and disruption chamber geometry on the fabrication of food Nanoemulsions by high pressure homogenization10.1021/ie2017898 ↗